Abemaciclib mesylate is a salt form of abemaciclib, an orally available cyclin-dependent kinase (CDK) inhibitor that targets CDK4 and CDK6, with potential antineoplastic activity. It inhibits retinoblastoma protein phosphorylation, thereby arresting the cell cycle in the G1 phase and suppressing cancer cell growth.
Content scope: Information here supports chemical identification and industrial supply, research, and manufacturing contexts. It is not a therapeutic claim, medical advice, or drug-use instructions.
Sourcing or supplying this compound?
List your inventory or post a purchase request
CAS 1231930-82-7
Abemaciclib
pharmaceutical raw material
Ganirelix
pharmaceutical raw material
Clofarabine
pharmaceutical raw material
5-trans-25-hydroxycholecalciferol
pharmaceutical raw material
PUBCHEM_44134997
pharmaceutical raw material
N-[5-[(4-ethylpiperazin-1-yl)methyl]-2-pyridinyl]-5-fluoro-4-(7-fluoro-2-methyl-3-propan-2-ylbenzimidazol-5-yl)pyrimidin-2-amine;methanesulfonic acid
NCJPFQPEVDHJAZ-UHFFFAOYSA-N
CCN1CCN(CC1)CC2=CN=C(C=C2)NC3=NC=C(C(=N3)C4=CC5=C(C(=C4)F)N=C(N5C(C)C)C)F.CS(=O)(=O)O